Balentine LLC Anavex Life Sciences Corp. Transaction History
Balentine LLC
- $2.2 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding AVXL
# of Institutions
152Shares Held
26.5MCall Options Held
674KPut Options Held
811K-
Black Rock Inc. New York, NY6.39MShares$34.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.55MShares$24.7 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$20.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.83MShares$9.96 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY1.01MShares$5.51 Million0.01% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $424M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...